DE69624815D1 - Untereinheitsimpfstoff gegen flavivirus infektion - Google Patents

Untereinheitsimpfstoff gegen flavivirus infektion

Info

Publication number
DE69624815D1
DE69624815D1 DE69624815T DE69624815T DE69624815D1 DE 69624815 D1 DE69624815 D1 DE 69624815D1 DE 69624815 T DE69624815 T DE 69624815T DE 69624815 T DE69624815 T DE 69624815T DE 69624815 D1 DE69624815 D1 DE 69624815D1
Authority
DE
Germany
Prior art keywords
virus
unit
glycoprotein
proteins
retain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69624815T
Other languages
English (en)
Other versions
DE69624815T2 (de
Inventor
M Ivy
Eileen Nakano
David Clements
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hawaii Biotechnology Group Inc
Original Assignee
Hawaii Biotechnology Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hawaii Biotechnology Group Inc filed Critical Hawaii Biotechnology Group Inc
Application granted granted Critical
Publication of DE69624815D1 publication Critical patent/DE69624815D1/de
Publication of DE69624815T2 publication Critical patent/DE69624815T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE1996624815 1995-05-24 1996-05-24 Untereinheitsimpfstoff gegen flavivirus infektion Expired - Lifetime DE69624815T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44873495A 1995-05-24 1995-05-24
US48880795A 1995-06-07 1995-06-07
US50046995A 1995-07-10 1995-07-10
PCT/US1996/007627 WO1996037221A1 (en) 1995-05-24 1996-05-24 Subunit vaccine against flavivirus infection

Publications (2)

Publication Number Publication Date
DE69624815D1 true DE69624815D1 (de) 2002-12-19
DE69624815T2 DE69624815T2 (de) 2003-07-10

Family

ID=27412379

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1996624815 Expired - Lifetime DE69624815T2 (de) 1995-05-24 1996-05-24 Untereinheitsimpfstoff gegen flavivirus infektion

Country Status (10)

Country Link
US (1) US6165477A (de)
EP (1) EP0836482B1 (de)
AT (1) ATE227584T1 (de)
AU (1) AU716676B2 (de)
CA (1) CA2224724C (de)
DE (1) DE69624815T2 (de)
DK (1) DK0836482T3 (de)
ES (1) ES2184869T3 (de)
PT (1) PT836482E (de)
WO (1) WO1996037221A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
CU22666A1 (es) * 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
EP1005363B1 (de) * 1997-07-31 2006-03-29 Hawaii Biotech, Inc. Rekombinante dimerische hüllproteine als impfstoff gegen eine flavivirale infektion
AU2002300271B8 (en) * 1997-07-31 2006-08-10 Hawaii Biotech, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
FR2767324B1 (fr) * 1997-08-14 2001-04-06 Pasteur Institut Utilisation de proteines d'enveloppe recombinantes pour le diagnostic du virus de la dengue
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
DE69934583T2 (de) 1998-06-04 2007-10-04 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
EP1263965B1 (de) * 2000-02-16 2011-09-28 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Avirulente, immunogene flavivirus-chimäre
AU2001267349A1 (en) * 2000-04-14 2001-10-30 Cistem Biotechnologies Gmbh Pharmaceutical preparations comprising modified peptides
US6682909B2 (en) * 2000-09-13 2004-01-27 Hawaii Biotech, Inc. Immunogenic composition of hepatitis C and methods of use thereof
AU2002309508A1 (en) * 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
WO2003060088A2 (en) * 2002-01-15 2003-07-24 Acambis, Inc. Viral vaccine production method
NZ535690A (en) 2002-02-26 2009-04-30 Maxygen Inc Novel flavivirus antigens
US7785799B2 (en) * 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
ATE428437T1 (de) * 2002-11-05 2009-05-15 Pasteur Institut Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen
US20050287170A1 (en) * 2002-12-11 2005-12-29 Hawaii Biotech, Inc. Subunit vaccine against West Nile viral infection
AU2003300831A1 (en) * 2002-12-11 2004-06-30 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
DK1685251T3 (en) * 2003-10-10 2014-03-24 Powderject Vaccines Inc Nucleic acid
US20070269461A1 (en) * 2004-01-04 2007-11-22 Sudhanshu Vrati Recombinant Vaccine Against Japanese Encephalitis Virus (Jev) Infection and a Method Thereof
US8900644B2 (en) * 2004-12-22 2014-12-02 Colgate-Palmolive Company Oral care compositions containing compounds from magnolia and hops extracts
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
EP2234624B1 (de) * 2008-01-11 2018-06-20 Inovio Pharmaceuticals, Inc. Neue impfstoffe gegen mehrere subtypen des dengue-virus
US20120141520A1 (en) 2009-05-31 2012-06-07 Beth-Ann Coller Recombinant subunit west nile virus vaccine for protection of human subjects
JP6057460B2 (ja) 2009-08-31 2017-01-11 ジェン−プローブ・インコーポレーテッド デングウイルスアッセイ
WO2012027473A2 (en) * 2010-08-24 2012-03-01 The University Of North Carolina At Chapel Hill Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens
SG189048A1 (en) * 2010-10-29 2013-05-31 Merck Sharp & Dohme Recombinant subunit dengue virus vaccine
KR102389908B1 (ko) 2013-03-15 2022-04-26 다케다 백신즈 인코포레이티드 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법
US11434261B2 (en) 2016-07-27 2022-09-06 Hawaii Biotech Inc. Optimized Zika virus envelope gene and expression thereof
BR112021003962A2 (pt) 2018-09-05 2021-05-25 Takeda Vaccines, Inc. dose unitária de vacina contra dengue e sua administração
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
US5013652A (en) * 1986-10-14 1991-05-07 Genex Corporation Composite yeast vectors
IL91304A0 (en) * 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
FR2665710A1 (fr) * 1990-08-10 1992-02-14 Pasteur Institut Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques.
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
WO1992003161A1 (en) * 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection

Also Published As

Publication number Publication date
ATE227584T1 (de) 2002-11-15
CA2224724C (en) 2007-12-04
DE69624815T2 (de) 2003-07-10
WO1996037221A1 (en) 1996-11-28
ES2184869T3 (es) 2003-04-16
AU6023996A (en) 1996-12-11
EP0836482B1 (de) 2002-11-13
CA2224724A1 (en) 1996-11-28
PT836482E (pt) 2003-02-28
US6165477A (en) 2000-12-26
EP0836482A1 (de) 1998-04-22
AU716676B2 (en) 2000-03-02
DK0836482T3 (da) 2003-02-17
EP0836482A4 (de) 1999-09-01

Similar Documents

Publication Publication Date Title
DE69624815D1 (de) Untereinheitsimpfstoff gegen flavivirus infektion
Rey et al. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution
Pugachev et al. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection
MY109299A (en) Recombinant pox virus encoding flaviviral structural proteins
DK0604566T3 (da) Kimærisk og/eller vækstbegrænsede flavivirus
US8153360B2 (en) Flavivirus fusion inhibitors
WO1999006068A3 (en) Recombinant dimeric envelope vaccine against flaviviral infection
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
RU2000107129A (ru) Химерическая вакцина против вируса клещевого энцефалита
JP2003525564A5 (de)
Flamand et al. Expression and secretion of Japanese encephalitis virus nonstructural protein NS1 by insect cells using a recombinant baculovirus
Delenda et al. Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells
EP2086526B1 (de) Herbeiführung einer Immunreaktion gegen das Dengue-Virus mithilfe eines prime-boost Verfahrens
AU718740B2 (en) Polyvalent anti-dengue vaccine
FI953581A (fi) Tick-Borne Enzephalitis (TBE) -viruksen infektoiva cDNA-klooni, siitä johdettu yhdistelmärokote ja sen valmistus
WO2022104081A3 (en) Modified secreted hepatitis c virus (hcv) e1e2 glycoproteins and methods of use thereof
MXPA98003840A (en) Vaccine polivalent anti-den
Kelly et al. Recombinant vaccine against dengue virus
PJGACHEV et al. Double-Subgenomic Sindbis Virus Recombinants Expressing Immunogenic Proteins of Japanese Encephalitis Virus lnduce Significant Protection in Mice against Lethal JEV Infection

Legal Events

Date Code Title Description
8364 No opposition during term of opposition